CFRX Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-02-14 | Messinger Michael | officer: Chief Financial Officer | 25,000 | A-Award | A | 25,000 | 5.04 | 126,000.00 |
| 2022-05-17 | Barlow Jane F | director: | 42,000 | A-Award | A | 42,000 | 3.35 | 140,700.00 |
| 2022-05-17 | Sucoff Cary | director: | 42,000 | A-Award | A | 42,000 | 3.35 | 140,700.00 |
| 2022-05-17 | OTTO MICHAEL J. | director: | 42,000 | A-Award | A | 42,000 | 3.35 | 140,700.00 |
| 2022-05-17 | Low David N. | director: | 42,000 | A-Award | A | 42,000 | 3.35 | 140,700.00 |
| 2022-05-17 | GILMAN STEVEN C | director: | 42,000 | A-Award | A | 42,000 | 3.35 | 140,700.00 |
| 2022-05-17 | BARER SOL J | director: | 42,000 | A-Award | A | 42,000 | 3.35 | 140,700.00 |
| 2022-05-17 | Aklog Lishan | director: | 42,000 | A-Award | A | 42,000 | 3.35 | 140,700.00 |
| 2022-02-15 | Pomerantz Roger | director, officer: Chief Executive Officer | 500,000 | A-Award | A | 500,000 | 3.33 | 1,665,000.00 |
| 2022-02-15 | Messinger Michael | officer: Chief Financial Officer | 165,000 | A-Award | A | 165,000 | 3.33 | 549,450.00 |
| 2022-02-15 | Cassino Cara M | officer: Chief Medical Officer | 160,000 | A-Award | A | 160,000 | 3.33 | 532,800.00 |
| 2022-02-15 | Bogdanos Natalie | officer: General Counsel | 125,000 | A-Award | A | 125,000 | 3.33 | 416,250.00 |
| 2021-05-18 | Sucoff Cary | director | 25,000 | A-Award | A | 25,000 | 3.86 | 96,500.00 |
| 2021-05-18 | OTTO MICHAEL J. | director | 25,000 | A-Award | A | 25,000 | 3.86 | 96,500.00 |
| 2021-05-18 | Low David N. | director | 25,000 | A-Award | A | 25,000 | 3.86 | 96,500.00 |
| 2021-05-18 | GILMAN STEVEN C | director | 25,000 | A-Award | A | 25,000 | 3.86 | 96,500.00 |
| 2021-05-18 | BARER SOL J | director | 25,000 | A-Award | A | 25,000 | 3.86 | 96,500.00 |
| 2021-05-18 | Aklog Lishan | director | 25,000 | A-Award | A | 25,000 | 3.86 | 96,500.00 |
| 2021-04-08 | Messinger Michael | officer: Chief Financial Officer | 80,000 | A-Award | A | 80,000 | 4.31 | 344,800.00 |
| 2021-04-08 | Cassino Cara M | officer: Chief Medical Officer | 90,000 | A-Award | A | 90,000 | 4.31 | 387,900.00 |
| 2021-04-08 | Cassino Cara M | officer: Chief Medical Officer | 80,000 | A-Award | A | 80,000 | 4.31 | 344,800.00 |
| 2021-04-08 | Bogdanos Natalie | officer: General Counsel | 70,000 | A-Award | A | 70,000 | 4.31 | 301,700.00 |
| 2021-04-08 | Pomerantz Roger | director, officer: Chief Executive Officer | 254,000 | A-Award | A | 254,000 | 4.31 | 1,094,740.00 |
| 2021-02-08 | Barlow Jane F | director | 16,000 | A-Award | A | 16,000 | 5.89 | 94,240.00 |
| 2021-02-08 | Barlow Jane F | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2020-06-15 | Aklog Lishan | director | 16,000 | A-Award | A | 16,000 | 5.77 | 92,320.00 |
| 2020-06-15 | Aklog Lishan | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2020-06-11 | Messinger Michael | officer: Chief Financial Officer | 75,000 | A-Award | A | 75,000 | 5.23 | 392,250.00 |
| 2020-05-12 | BARER SOL J | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2020-05-12 | GILMAN STEVEN C | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2020-05-12 | Low David N. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2020-05-12 | OTTO MICHAEL J. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2020-05-12 | Sucoff Cary | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2020-02-21 | Pomerantz Roger | director, officer: Chief Executive Officer | 0 | 0 | 0.00 | 0.00 | ||
| 2020-02-19 | Dong Nancy | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2020-02-19 | Messinger Michael | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2020-02-19 | Cassino Cara M | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2020-02-19 | Bogdanos Natalie | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2019-12-13 | Messinger Michael | officer: Chief Financial Officer | 19,091 | P-Purchase | A | 5,000 | 0.37 | 1,850.00 |
| 2019-12-13 | Sucoff Cary | director | 62,000 | P-Purchase | A | 50,000 | 0.39 | 19,500.00 |
| 2019-12-13 | Low David N. | director | 370,550 | P-Purchase | A | 300,000 | 0.43 | 129,000.00 |
| 2019-08-13 | BARER SOL J | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-08-13 | Sucoff Cary | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-08-13 | OTTO MICHAEL J. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-08-13 | Low David N. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-08-13 | GILMAN STEVEN C | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-05-07 | Sucoff Cary | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-05-07 | BLECH ISAAC | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-05-07 | Low David N. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-05-07 | BARER SOL J | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-05-07 | OTTO MICHAEL J. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-05-07 | GILMAN STEVEN C | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2019-04-02 | Pomerantz Roger | director, officer: Chief Executive Officer | 0 | 0 | 0.00 | 0.00 | ||
| 2019-02-05 | GILMAN STEVEN C | director, officer: CEO | 0 | 0 | 0.00 | 0.00 | ||
| 2019-02-05 | Bogdanos Natalie | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2019-02-05 | Cassino Cara M | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2019-02-05 | Dong Nancy | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2019-02-05 | Messinger Michael | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2018-12-04 | Fosun Industrial Co., Ltd | 10 percent owner | 7,900,000 | S-Sale | D | 600,000 | 2.04 | 1,224,000.00 |
| 2018-12-04 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10 percent owner | 7,900,000 | S-Sale | D | 600,000 | 2.04 | 1,224,000.00 |
| 2017-07-25 | Fosun Industrial Co., Ltd | 10 percent owner | 0 | D | 4,250,000 | 1.55 | 6,587,500.00 | |
| 2017-07-25 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10 percent owner | 0 | I | 4,250,000 | 1.55 | 6,587,500.00 | |
| 2018-05-08 | BLECH ISAAC | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2018-05-08 | Sucoff Cary | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2018-05-08 | Pomerantz Roger | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2018-05-08 | OTTO MICHAEL J. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2018-05-08 | Low David N. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2018-05-08 | BARER SOL J | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2018-02-01 | GILMAN STEVEN C | director, officer: CEO | 0 | 0 | 0.00 | 0.00 | ||
| 2018-02-01 | Bogdanos Natalie | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2018-02-01 | Cassino Cara M | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2018-02-01 | Dong Nancy | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2018-02-01 | Muntner Joshua B | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2018-02-01 | Messinger Michael | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2017-11-06 | Ricciardi Lisa | director, officer: Chief Operating Officer | 0 | 0 | 0.00 | 0.00 | ||
| 2017-07-25 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10 percent owner | 8,500,000 | I | 0 | 0.00 | 0.00 | |
| 2017-07-25 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10 percent owner | 0 | I | 4,250,000 | 1.55 | 6,587,500.00 | |
| 2017-07-25 | Fosun Industrial Co., Ltd | 10 percent owner | 8,500,000 | D | 0 | 0.00 | 0.00 | |
| 2017-07-25 | Fosun Industrial Co., Ltd | 10 percent owner | 0 | D | 4,250,000 | 1.55 | 6,587,500.00 | |
| 2017-07-25 | BLECH ISAAC | director | 16,000 | P-Purchase | A | 16,000 | 1.24 | 19,840.00 |
| 2017-07-25 | BLECH ISAAC | director | 8,000 | P-Purchase | A | 8,000 | 1.55 | 12,400.00 |
| 2017-07-25 | Muntner Joshua B | officer: SVP Business Development | 2,000 | P-Purchase | A | 2,000 | 1.24 | 2,480.00 |
| 2017-07-25 | Muntner Joshua B | officer: SVP Business Development | 1,000 | P-Purchase | A | 1,000 | 1.55 | 1,550.00 |
| 2017-07-25 | Messinger Michael | officer: SVP Finance | 14,091 | P-Purchase | A | 800 | 1.24 | 992.00 |
| 2017-07-25 | Messinger Michael | officer: SVP Finance | 400 | P-Purchase | A | 400 | 1.55 | 620.00 |
| 2017-07-25 | Cassino Cara M | officer: Chief Medical Officer | 8,000 | P-Purchase | A | 8,000 | 1.24 | 9,920.00 |
| 2017-07-25 | Cassino Cara M | officer: Chief Medical Officer | 4,000 | P-Purchase | A | 4,000 | 1.55 | 6,200.00 |
| 2017-07-25 | Bogdanos Natalie | officer: General Counsel | 800 | P-Purchase | A | 800 | 1.24 | 992.00 |
| 2017-07-25 | Bogdanos Natalie | officer: General Counsel | 400 | P-Purchase | A | 400 | 1.55 | 620.00 |
| 2017-07-25 | Sucoff Cary | director | 12,000 | P-Purchase | A | 12,000 | 1.24 | 14,880.00 |
| 2017-07-25 | Sucoff Cary | director | 6,000 | P-Purchase | A | 6,000 | 1.55 | 9,300.00 |
| 2017-07-25 | Ricciardi Lisa | director | 9,600 | P-Purchase | A | 9,600 | 1.24 | 11,904.00 |
| 2017-07-25 | Ricciardi Lisa | director | 4,800 | P-Purchase | A | 4,800 | 1.55 | 7,440.00 |
| 2017-07-25 | Pomerantz Roger | director | 800 | P-Purchase | A | 800 | 1.24 | 992.00 |
| 2017-07-25 | Pomerantz Roger | director | 400 | P-Purchase | A | 400 | 1.55 | 620.00 |
| 2017-07-25 | OTTO MICHAEL J. | director | 8,000 | P-Purchase | A | 8,000 | 1.24 | 9,920.00 |
| 2017-07-25 | OTTO MICHAEL J. | director | 4,000 | P-Purchase | A | 4,000 | 1.55 | 6,200.00 |
| 2017-07-25 | Low David N. | director | 70,550 | P-Purchase | A | 40,000 | 1.24 | 49,600.00 |
| 2017-07-25 | Low David N. | director | 20,000 | P-Purchase | A | 20,000 | 1.55 | 31,000.00 |
| 2017-07-25 | BARER SOL J | director | 815,933 | P-Purchase | A | 40,000 | 1.24 | 49,600.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.